(Q37697337)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20179152%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

review article

1 reference

title

Genetic redirection of T cells for cancer therapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20179152%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20179152%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

author name string

Jennifer A Westwood

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20179152%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

publication date

23 February 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20179152%20AND%20SRC:MED&resulttype=core&format=json

Journal of Leukocyte Biology

18 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20179152%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

volume

87

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20179152%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20179152%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

page(s)

791-803

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20179152%20AND%20SRC:MED&resulttype=core&format=json

Supernatural T cells: genetic modification of T cells for cancer therapy

18 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

Targeting tumours with genetically enhanced T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

Antitumor activity of dual-specific T cells and influenza virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

Second-generation anti-carcinoembryonic antigen designer T cells resist activation-induced cell death, proliferate on tumor contact, secrete cytokines, and exhibit superior antitumor activity in vivo: a preclinical evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

Immunotherapy of metastatic melanoma using genetically engineered GD2-specific T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

4-1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood T cells against B-cell malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

Target antigen expression on a professional antigen-presenting cell induces superior proliferative antitumor T-cell responses via chimeric T-cell receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

Redirected activity of human antitumor chimeric immune receptors is governed by antigen and receptor expression levels and affinity of interaction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

The Lewis-Y carbohydrate antigen is expressed by many human tumors and can serve as a target for genetically redirected T cells despite the presence of soluble antigen in serum

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

Adoptive transfer of T cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

Retargeting of human T cells to tumor-associated MUC1: the evolution of a chimeric antigen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

Conversion of a tumor-binding peptide identified by phage display to a functional chimeric T cell antigen receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

Primary human T lymphocytes engineered with a codon-optimized IL-15 gene resist cytokine withdrawal-induced apoptosis and persist long-term in the absence of exogenous cytokine

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

Transduction of an IL-2 gene into human melanoma-reactive lymphocytes results in their continued growth in the absence of exogenous IL-2 and maintenance of specific antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

Adoptive cell therapy for patients with melanoma, using tumor-infiltrating lymphocytes genetically engineered to secrete interleukin-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

Selective expansion of genetically modified T cells using an antibody/interleukin-2 receptor chimera.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

T cell growth control using hapten-specific antibody/interleukin-2 receptor chimera.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

Genetic manipulation of tumor-specific cytotoxic T lymphocytes to restore responsiveness to IL-7.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

Lentiviral vector conferring resistance to mycophenolate mofetil and sensitivity to ganciclovir for in vivo T-cell selection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

Efficiency of T-cell receptor expression in dual-specific T cells is controlled by the intrinsic qualities of the TCR chains within the TCR-CD3 complex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

Gene-engineered varicella-zoster virus reactive CD4+ cytotoxic T cells exert tumor-specific effector function

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

Dual-specific T cells combine proliferation and antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

Adoptive immunotherapy of disseminated leukemia with TCR-transduced, CD8+ T cells expressing a known endogenous TCR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

Phoenix-ampho outperforms PG13 as retroviral packaging cells to transduce human T cells with tumor-specific receptors: implications for clinical immunogene therapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

Reprogramming T lymphocytes for melanoma adoptive immunotherapy by T-cell receptor gene transfer with lentiviral vectors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

Use of a lentivirus/VSV pseudotype virus for highly efficient genetic redirection of human peripheral blood lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

Use of recombinant lentivirus pseudotyped with vesicular stomatitis virus glycoprotein G for efficient generation of human anti-cancer chimeric T cells by transduction of human peripheral blood lymphocytes in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

Lentiviral vector design for optimal T cell receptor gene expression in the transduction of peripheral blood lymphocytes and tumor-infiltrating lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

Sleeping Beauty transposon-mediated engineering of human primary T cells for therapy of CD19+ lymphoid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

Redirecting specificity of T-cell populations for CD19 using the Sleeping Beauty system

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

Efficient nonviral Sleeping Beauty transposon-based TCR gene transfer to peripheral blood lymphocytes confers antigen-specific antitumor reactivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

Optimization of the PiggyBac transposon system for the sustained genetic modification of human T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

Genome-wide mapping of PiggyBac transposon integrations in primary human T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

Transfer of mRNA encoding recombinant immunoreceptors reprograms CD4+ and CD8+ T cells for use in the adoptive immunotherapy of cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

Adoptive immunotherapy using human peripheral blood lymphocytes transferred with RNA encoding Her-2/neu-specific chimeric immune receptor in ovarian cancer xenograft model

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

Gene-engineered T cells as a superior adjuvant therapy for metastatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

Eradication of established B-cell lymphoma by CD19-specific murine T cells is dependent on host lymphopenic environment and can be mediated by CD4+ and CD8+ T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

Medulloblastomas expressing IL13Ralpha2 are targets for IL13-zetakine+ cytolytic T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

Regression of experimental medulloblastoma following transfer of HER2-specific T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

In vivo imaging and quantitation of adoptively transferred human antigen-specific T cells transduced to express a human norepinephrine transporter gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

Monitoring the efficacy of adoptively transferred prostate cancer-targeted human T lymphocytes with PET and bioluminescence imaging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

Imaging immune response in vivo: cytolytic action of genetically altered T cells directed to glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

Adoptive transfer of gene-engineered CD4+ helper T cells induces potent primary and secondary tumor rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

Sustained antigen-specific antitumor recall response mediated by gene-modified CD4+ T helper-1 and CD8+ T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

Induction of human cytotoxic T lymphocytes by artificial antigen-presenting cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

Antigen-independent and antigen-dependent methods to numerically expand CD19-specific CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

Single-pass, closed-system rapid expansion of lymphocyte cultures for adoptive cell therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

Human monocytes expressing a CEA-specific chimeric CD64 receptor specifically target CEA-expressing tumour cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

Tumor-specific dendritic cells generated by genetic redirection of Toll-like receptor signaling against the tumor-associated antigen, erbB2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

Transfection with mRNA for CD19 specific chimeric antigen receptor restores NK cell mediated killing of CLL cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

Chimeric NKG2D modified T cells inhibit systemic T-cell lymphoma growth in a manner involving multiple cytokines and cytotoxic pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

Immunotherapy with chimeric NKG2D receptors leads to long-term tumor-free survival and development of host antitumor immunity in murine ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

Chimeric NKG2D receptor-expressing T cells as an immunotherapy for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

2B4 (CD244) signaling via chimeric receptors costimulates tumor-antigen specific proliferation and in vitro expansion of human T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

A new way to generate cytolytic tumor-specific T cells: electroporation of RNA coding for a T cell receptor into T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

Recognition of NY-ESO-1+ tumor cells by engineered lymphocytes is enhanced by improved vector design and epigenetic modulation of tumor antigen expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

Characterization of genetically modified T-cell receptors that recognize the CEA:691-699 peptide in the context of HLA-A2.1 on human colorectal cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

T-cell receptor gene therapy of established tumors in a murine melanoma model

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

TCR gene therapy of spontaneous prostate carcinoma requires in vivo T cell activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

Cancer regression in patients after transfer of genetically engineered lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

Human TCR that incorporate CD3zeta induce highly preferred pairing between TCRalpha and beta chains following gene transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

Alpha beta T cell receptor transfer to gamma delta T cells generates functional effector cells without mixed TCR dimers in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

Retrovirus vector silencing is de novo methylase independent and marked by a repressive histone code

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

Methylation-mediated proviral silencing is associated with MeCP2 recruitment and localized histone H3 deacetylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

De novo methylation, expression, and infectivity of retroviral genomes introduced into embryonal carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

Mutation of CpGs in the murine stem cell virus retroviral vector long terminal repeat represses silencing in embryonic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

Lack of specific gamma-retroviral vector long terminal repeat promoter silencing in patients receiving genetically engineered lymphocytes and activation upon lymphocyte restimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

Gene-modified T cells for adoptive immunotherapy of renal cell cancer maintain transgene-specific immune functions in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

Long-term functionality of TCR-transduced T cells in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

A chimeric receptor that selectively targets membrane-bound carcinoembryonic antigen (mCEA) in the presence of soluble CEA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

Antitumor activity of chimeric immunoreceptor gene-modified Tc1 and Th1 cells against autologous carcinoembryonic antigen-expressing colon cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

Generation of antitumor responses by genetic modification of primary human T cells with a chimeric NKG2D receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

Process validation and clinical evaluation of a protocol to generate gene-modified T lymphocytes for imunogene therapy for metastatic renal cell carcinoma: GMP-controlled transduction and expansion of patient's T lymphocytes using a carboxy anhydras

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

Clinical-scale lentiviral vector transduction of PBL for TCR gene therapy and potential for expression in less-differentiated cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

Genetically engineered T cells to target EGFRvIII expressing glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

Targeting of tumor cells expressing the prostate stem cell antigen (PSCA) using genetically engineered T-cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

Rhabdomyosarcoma lysis by T cells expressing a human autoantibody-based chimeric receptor targeting the fetal acetylcholine receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

Activated T-cell-mediated immunotherapy with a chimeric receptor against CD38 in B-cell non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

Redirecting therapeutic T cells against myelin-specific T lymphocytes using a humanized myelin basic protein-HLA-DR2-zeta chimeric receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

Adoptive therapy with redirected primary regulatory T cells results in antigen-specific suppression of arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

Manufacturing of gene-modified cytotoxic T lymphocytes for autologous cellular therapy for lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

Coexpression of the uracil phosphoribosyltransferase gene with a chimeric human nerve growth factor receptor/cytosine deaminase fusion gene, using a single retroviral vector, augments cytotoxicity of transduced human T cells exposed to 5-fluorocytos

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.1209824

21 January 2018

Identifiers

DOI

10.1189/JLB.1209824

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20179152%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1 reference